

PTO/SB/08A		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary) MAR 18 2002 TRADEMARK OFFICE		Application Number	10/003,907
		Filing Date	November 2, 2001
		Confirmation Number	7717
		First Named Inventor	S. Srikumaran
Sheet 1	of 4	Attorney Docket No.	UNL 3060.2

RECEIVED  
 APR 04 2002  
 TECH CENTER 1600/2900

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code <sup>2</sup> (if known)		
BOL	1	5,462,734		Letchworth, III et al.	10-31-1995
BOL	2	5,676,951		Rijsewijk et al.	10-14-1997
BOL	3	5,830,464		Srivastava	11-03-1998
BOL	4	5,837,251		Srivastava	11-17-1998
BOL	5	5,935,576		Srivastava	08-10-1999
BOL	6	5,948,646		Srivastava	09-07-1999

Class / Subclass

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office	Number <sup>4</sup>	Kind Code <sup>2</sup> (if known)			
BOL	7		WO 97/10001		Srivastava	03-20-1997	
BOL	8		WO 98/34641		Srivastava et al.	08-13-1998	

Class / Subclass

Examiner Signature	<i>Deogen L</i>	Date Considered	03/28/2003
--------------------	-----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary) MAR 18 2002 2nd OFFICE		Application Number	10/003,907
		Filing Date	November 2, 2001
		Confirmation Number	7717
		First Named Inventor	S. Srikumaran
Sheet	4	of	4
		Attorney Docket No.	UNL 3060.2

RECEIVED

TECH CENTER 1600/2900

APR 04 2002

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
BOLi	9	ARNOLD et al., Influences of Transporter Associated with Antigen Processing (TAP) on the Repertoire of Peptides Associated with the Endoplasmic Reticulum-resident Protein gp96, <i>J. Exp. Med.</i> , Aug. 1997, pp. 461-66, Vol. 186, No. 3, The Rockefeller University Press	
BOLi	10	BAMFORD et al., Peptide motif of a cattle MHC class I mole, <i>Immunology Letters</i> , 1995, pp. 129-36, Vol. 45, Elsevier Science	
BOLi	11	BLACHERE et al., Heat Shock Protein-Peptide Complexes, Reconstituted In Vitro, Elicit Peptide-specific Cytotoxic T Lymphocyte Response and Tumor Immunity, <i>J. Exp. Med.</i> , Oct. 1997, pp. 1315-22, Vol. 186, No. 8, The Rockefeller University Press	
BOLi	12	CRAIG, Chaperones: Helpers Along the Pathways to Protein Folding, <i>Science</i> , June 1993, pp. 1902-03, Vol. 260	
BOLi	13	GADDUM et al., Peptide motifs from three cattle MHC (BoLA) class I antigens, <i>Immunogenetics</i> , 1996, pp. 238-39, Vol. 43	
BOLi	14	GETHING et al., Protein folding in the cell, <i>Nature</i> , Jan. 1992, pp. 33-45, Vol. 355	
BOLi	15	HEDGE et al., Peptide motif of the cattle MHC class I antigen BoLA-A11, <i>Immunogenetics</i> , 1995, pp. 302-03, Vol. 42	
BOLi	16	HEIKE et al., Heat shock protein-peptide complexes for use in vaccines, <i>Journal of Leukocyte</i> , Aug. 1996, pp. 153-58, Vol. 60, No. 2, Society for Leukocyte Biology	
BOLi	17	HUNT et al., Conserved features of eukaryotic hsp70 genes revealed by comparison with the nucleotide sequence of human hsp70, <i>Proc. Natl. Acad. Sci.</i> , Oct. 1995, pp. 6455-59, Vol. 82	
BOLi	18	ISREAL et al., Epitope specificity and protective efficacy of the bovine immune response to bovine herpesvirus-1 glycoprotein vaccines, <i>Vaccine</i> , Aug. 1988, pp. 349-56, Vol. 6	
BOLi	19	JANETZKI et al., Immunization of Cancer Patients with Autologous Cancer-Derived Heat Shock Protein gp96 Preparations: A Pilot Study, <i>J. Cancer</i> , 2000, pp. 232-38, Vol. 88	
BOLi	20	KONEN-WAISMANN, Self Heat-Shock Protein (hsp60) Peptide Serves in a Conjugate Vaccine against a Lethal Pneumococcal Infection, <i>Jour. Infect. Dis.</i> , Feb. 1999, pp. 403-13, Vol. 179, No. 2	
Examiner Signature	D. A. Owen		Date Considered
		03/28/2003	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

RECEIVED

PTO/SB/08A		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary) MAR 18 2002		Application Number	10/003,907
		Filing Date	November 2, 2000
		Confirmation Number	7717
		First Named Inventor	S. Srikumaran
Sheet 3 of 4	Attorney Docket No.	UNL 3060.2	

BQL:	21	LAMMERT et al., Expression levels of stress protein gp96 are not limiting for major histocompatibility complex class I-restricted antigen presentation, <i>Eur. J. Immunol.</i> , 1996, pp. 875-79, Vol. 26	
BQL:	22	LINDQUIST et al., The Heat-Shock Proteins, <i>Annu. Rev. Genet.</i> , 1988, pp. 631-677, Vol. 22	
BQL:	23	MENG et al., HBV-specific peptide associated with heat-shock protein gp96, <i>The Lancet</i> , 2001, pp. 528-29, Vol. 357, No. 9255	
BQL:	24	MORAN et al., The major heat-shock protein (hsp70) gene family: related sequences in mouse, <i>Drosophila</i> , and yeast, <i>Can. J. Biochem.</i> , 1983, pp. 488-99, Vol. 61	
BQL:	25	NIELAND et al., Isolation of an immunodominant viral peptide that is endogenously bound to the stress protein GP96/GRP94, <i>Proc. Natl. Acad. Sci.</i> , June 1996, pp. 6135-39, Vol. 93	
BQL:	26	SCHILD et al., Stress proteins and immunity mediated by cytotoxic T lymphocytes, <i>Cur. Opin. Immunol.</i> , 1999, pp. 109-13, Vol. 11	
BQL:	27	SETTE et al., HLA supertypes and supermotifs: a functional perspective on HLA polymorphism, <i>Curr. Opin. Immunol.</i> , 1998, pp. 478-82, Vol. 10	
BQL:	28	SMITH et al., Antisense RNA inhibition of polygalacturonase gene expression in transgenic tomatoes, <i>Nature</i> , 1988, pp. 724-26, Vol. 334, No. 6184	
BQL:	29	SPEE et al., TAP-translocated peptides specifically bind proteins in the endoplasmic reticulum, including gp96, protein disulfide isomerase and calreticulin, <i>Eur. J. Immunol.</i> , 1997, pp. 2441-49, Vol. 27	
BQL:	30	SPONAAS et al., Immunization with gp96 from <i>Listeria monocytogenes</i> -Infected Mice is Due to N-Formylated Listerial Peptides, <i>J. Immunology</i> , 2001, pp. 6480-86, Vol. 167, No. 11	
BQL:	31	SRIVASTAVA et al., Tumor rejection antigens of chemically induced sarcomas of inbred mice, <i>Proc. Natl. Acad. Sci.</i> , May 1986, pp. 3407-11, Vol. 83	
BQL:	32	SRIVASTAVA et al., Heat shock proteins transfer peptides during antigen processing and CTL priming, <i>Immunogenetics</i> , 1994, pp. 93-98, Vol. 39	
BQL:	33	SRIVASTAVA, Peptide-Binding Heat Shock Proteins in the Endoplasmic Reticulum: Role in Immune Response to Cancer and in Antigen Presentation, <i>Adv. Cancer Res.</i> , 1993, pp. 153-77, Vol. 62	
BQL:	34	SRIVASTAVA, Purification of Heat Shock Protein-Peptide Complexes for Use in Vaccination against Cancers and Intracellular Pathogens, <i>Methods</i> , 1997, pp. 165-71, Vol. 12, Academic Press	

Examiner Signature	Ba. Buzli	Date Considered	03/28/2003
--------------------	-----------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

RECEIVED

PTO/SB/08A		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary) MAR 18 2002 U.S. PATENT & TRADEMARK OFFICE		Application Number	10/003,907
		Filing Date	November 2, 2001
		Confirmation Number	7717
		First Named Inventor	S. Srikumaran
Sheet	4	of	4
		Attorney Docket No.	UNL 3060.2

BOL	35	SUTO et al., A Mechanism for the Specific Immunogenicity of Heat Shock Protein-Chaperoned Peptides, <i>Science</i> , Sep. 1995, pp. 1585-88, Vol. 269	
BOL	36	TAMURA et al., Immunotherapy of Tumors with Autologous Tumor-Derived Heat Shock Protein Preparations, <i>Science</i> , Oct. 1997, pp. 117-20, Vol. 278	
BOL	37	WEARSCH et al., Structural Transitions Accompanying the Activation of Peptide Binding to the Endoplasmic Reticulum Hsp90 Chaperone GRP94, <i>Biochemistry</i> , 1998, pp. 5709-19, Vol. 37, No. 16	
BOL	38	WELCH, How Cells Respond to Stress, <i>Scientific American</i> , May 1993, pp. 56-64	
BOL	39	YOUNG, Stress Proteins and Immunology, <i>Ann. Rev. Immunol.</i> , 1990, pp. 401-20, Vol. 8	
BOL	40	ZATECHKA, JR. et al., Identification of murine cytotoxic T-lymphocyte epitopes of bovine herpesvirus 1, <i>Vaccine</i> , 1999, pp. 686-94, Vol. 17	

Examiner Signature	<i>David L. ...</i>	Date Considered	03/28/2003
--------------------	---------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.